Abl Bio Inc.

Yuhan Corporation

I-mab Biopharma US Limited

Hyejin Chung

Yangsoon Lee

Eunsil Sung

Yeunju Kim

Eunyoung Park

Youngdon Pak

Byungje Sung

Eun-Jung Lee

Kyeongsu Park

Yong-Gyu Son

Jinhyung Ahn

Kyungjin Park

Donghoon Yeom

Daehae Song

Ui-Jung Jung

Seawon Ahn

Sang Hoon Lee

Juhee Kim

Moo Young Song

Jiseon Yoo

Jaehyun Eom

Na Rae Lee

Jaeho Jung

Minji Park

Eunjung Kim

Young Bong Park

Uijung Jung

Hyoju Choi

Yeryoung Yong

Wonjun Son

Dongin Kim

Lei Fang

Bora Lee

Wenqing Jiang

Jinwon Jung

Taewang Kim

YoungKwang Kim

Weon-Kyoo You

Sungwon An

Sang-Jun Ha

Myeong Joon Kim

Yoseob Lee

Chanmoo Lee

Junghyeon Hong

Weonkyoo You

Jun Hyun Jeong

Provided are an anti-4-1BB/anti-HER2 bispecific antibody, and a pharmaceutical composition and a method for treating and/or preventing a cancer using the same.

Anti-HER2/anti-4-1BB bispecific antibody and use thereof

Provided is an anti-4-1BB antibody or an antigen-binding fragment thereof, and uses thereof.

Anti-4-1BB antibody and use thereof

The present disclosure provides an anti-PD-L1/anti-4-1BB bispecific antibody capable to effectively block the interactions between PD-L1 and its receptor PD-1 and between 4-1BB and its ligand. The bispecific antibody may have high binding affinity to both of a PD-L1 protein and a 4-1BB protein.

Anti-PD-L1/anti-4-1BB bispecific antibodies and uses thereof

Provided are an anti-4-1BB/anti-EGFR bispecific antibody, and a pharmaceutical composition and a method for treating and/or preventing a cancer using the same.

Anti-EGFR/anti-4-1BB bispecific antibody

The present invention discloses an anti-ROR1 antibody specifically recognizing human and mouse ROR1. The monoclonal antibody can be usefully used for cancer targeting treatment including detection of various cancer expressing ROR1 through specific binding, and drug delivery to specific cancer, etc. as well as a cancer therapeutic agent, by inhibiting tumors.

Anti-ROR1 antibody and use thereof

The present invention relates to a bi-specific antibody that specifically binds to alpha-synuclein and IGF1R, and use of the bi-specific antibody for treating or diagnosing synucleinopathies associated with alpha-synuclein or alpha-synuclein aggregates. The IGF1R portion of the bi-specific antibody acts as a shuttle to penetrate the blood brain barrier, allowing the alpha-synuclein portion to exert its action in the brain. Further, the half-life of the bi-specific antibody may be extended to maintain efficacy over time.

Bispecific antibody to alpha-synuclein/insulin-like growth factor 1 receptor and use thereof

Provided is an anti-B7-H3 antibody specifically recognizing a B7-H3, which can be usefully as a cancer therapeutic agent, as having an inhibitory activity of an immune checkpoint which induces antibody-dependent cell-mediated cytotoxicity and T cell activation inhibited by B7-H3. In particular, the antibody having the inhibitory activity of an immune checkpoint can be used in combination with other immunoantibody therapeutic agents. In addition, it can be usefully used for cancer targeting treatment including detection of various cancers expressing B7-H3 through specific binding to B7-H3, and drug delivery to specific cancer, etc.

Anti-B7-H3 antibody and use thereof

Growing community of inventors

Seongnam-si, South Korea

Hyejin Chung